EDEM3: A Potential Drug Target and Biomarker (G80267)

Target Name: EDEM3

NCBI ID: G80267

EDEM3: A Potential Drug Target and Biomarker

Edem3, also known as EDEM3 variant 2, is a protein that is expressed in a variety of tissues throughout the body, including the brain, heart, kidneys, and liver. It is a member of the EDEM gene family, which is known for the development of essential memory and learning disorders. In this article, we will discuss the research on EDEM3 and its potential as a drug target or biomarker.

Potential Drug Target

EDEM3 has been identified as a potential drug target due to its involvement in a variety of cellular processes that are important for maintaining brain health and function. One of the key functions of EDEM3 is its role in the regulation of the blood-brain barrier, which is responsible for controlling the movement of substances into and out of the brain.

Studies have shown that the blood-brain barrier is critical for the delivery of drugs to the brain and for the regulation of factors that can affect brain health, such as inflammation and neurodegeneration. EDEM3 has been shown to play a key role in the regulation of the blood-brain barrier, and alterations in its expression have been linked to a variety of neurological and psychiatric disorders.

In addition to its role in the blood-brain barrier, EDEM3 has also been shown to be involved in the regulation of a variety of other cellular processes that are important for brain health and function. For example, it has been shown to play a key role in the regulation of cell survival, cell proliferation, and neurogenesis. It has also been shown to be involved in the regulation of intracellular signaling pathways, such as the production of reactive oxygen species (ROS) and the regulation of inflammation.

Potential Biomarker

EDEM3 has also been identified as a potential biomarker for a variety of neurological and psychiatric disorders. Studies have shown that changes in the expression of EDEM3 are associated with the development of a variety of disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

In addition to its potential as a drug target, EDEM3 is also a potential biomarker for a variety of disorders. Its expression has been shown to be associated with the development of a variety of disorders, including neurodegenerative disorders, mood disorders, and psychosis. Additionally, studies have shown that changes in the expression of EDEM3 are associated with the worsening of symptoms in individuals with schizophrenia and other psychiatric disorders.

Conclusion

In conclusion, EDEM3 is a protein that has been identified as a potential drug target and biomarker for a variety of neurological and psychiatric disorders. Its role in the regulation of the blood-brain barrier and its expression in a variety of tissues make it an attractive target for drug development. Further research is needed to fully understand the potential of EDEM3 as a drug and to determine its utility as a biomarker for a variety of disorders.

Protein Name: ER Degradation Enhancing Alpha-mannosidase Like Protein 3

Functions: Involved in endoplasmic reticulum-associated degradation (ERAD). Accelerates the glycoprotein ERAD by proteasomes, by catalyzing mannose trimming from Man8GlcNAc2 to Man7GlcNAc2 in the N-glycans (PubMed:25092655). May also participate in mannose trimming from all glycoproteins and not just misfolded ones targeted to ERAD (PubMed:34143952). May have alpha 1,2-mannosidase activity (By similarity)

More Common Targets